Liu Ping, Wei Zibai, He Xiaofeng, Yu Junyan, Tian Xiangyang, Chang Jianlan
Department of Oncology, Xiangya Hospital, Central South University Changsha 410008, China ; Department of Oncology, Peace Hospital of Changzhi Medical College Changzhi 046000, China.
Department of Oncology, Peace Hospital of Changzhi Medical College Changzhi 046000, China.
Int J Clin Exp Med. 2015 Feb 15;8(2):2357-63. eCollection 2015.
CD95 rs2234767 polymorphism in the promotor region of CD95 gene has been implicated in several studies of cervical cancer. However, the results have not been conclusively established.
The main aim of this study was to deal with the controversy with respect to the correlation between CD95 rs2234767 polymorphism and risk of cervical cancer through a meta-analysis.
Association studies that pertain to CD95 rs2234767 polymorphism and risk of cervical cancer were identified up to May 26, 2014. ORs and 95% CIs were calculated assuming AA versus GG, AA + AG versus GG, AA versus AG + GG, A versus G and AG versus GG genetic models.
A total of 5 case-control studies were included in this meta-analysis. Overall, no significant effect modification of cervical cancer risk was revealed either at the genotypic or the allelic level for CD95 rs2234767 polymorphism. This null association persisted in the stratified analysis of Asian population.
These findings revealed that CD95 rs2234767 polymorphism may not act as a causative agent of cervical cancer. Further evidence is needed to confirm our findings.
CD95基因启动子区域的CD95 rs2234767多态性在多项宫颈癌研究中受到关注。然而，结果尚未最终确定。
本研究的主要目的是通过荟萃分析解决CD95 rs2234767多态性与宫颈癌风险之间相关性的争议。
截至2014年5月26日，确定了与CD95 rs2234767多态性和宫颈癌风险相关的关联研究。在AA与GG、AA + AG与GG、AA与AG + GG、A与G以及AG与GG遗传模型下计算比值比（OR）和95%可信区间（CI）。
本荟萃分析共纳入5项病例对照研究。总体而言，CD95 rs2234767多态性在基因型或等位基因水平上均未显示出对宫颈癌风险有显著的效应修饰。在亚洲人群的分层分析中，这种无关联的情况仍然存在。
这些发现表明，CD95 rs2234767多态性可能不是宫颈癌的致病因素。需要进一步的证据来证实我们的发现。
